Completed PHASE3 INTERVENTIONAL 2-arm NCT00711880

A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.

A Double Blind, Randomised, Placebo Controlled Parallel Group Study of Cannabis Based Medicine Extract (CBME), in the Treatment of Peripheral Neuropathic Pain Characterised by Allodynia.

Sponsor: Jazz Pharmaceuticals

Conditions Pain Peripheral Neuropathy

Interventions Placebo Sativex®

Updated 8 times since 2017 Last updated: Apr 7, 2023 Started: May 31, 2002 Primary completion: Mar 31, 2004 Completion: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pain and Peripheral Neuropathy, this trial is completed. The trial is conducted by Jazz Pharmaceuticals and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2023 — Jul 2024 [monthly]

Completed PHASE3
Mar 2022 — May 2023 [monthly]

Completed PHASE3
Mar 2021 — Mar 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Mar 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jazz Pharmaceuticals

Data source: Jazz Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fazakerley, United Kingdom